The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. The ultimate goal is to identify targets for biomarker discovery and drug development for AD/ADRD.
This NOFO runs parallel with RFA-AG-25-023 , a NOFO with a similar scientific scope that utilizes the Exploratory/Developmental Grant (R21) mechanism.
Deadlines:
RFA-AG-25-022 Expiration Date November 02, 2024
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Nov 01, 2024
$2,500,000
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.